ATR-X mutations cause impaired nuclear location and altered DNA binding properties of the XNP/ATR-X protein.
Mutations in the XNP/ATR-X gene, located in Xq13.3, are associated with several X linked mental retardation syndromes, the best known being alpha thalassaemia with mental retardation (ATR-X). The XNP/ATR-X protein belongs to the family of SWI/SNF DNA helicases and contains three C2-C2 type zinc fingers of unknown function. Previous studies have shown that 65% of mutations of XNP have been found within the zinc finger domain (encoded by exons 7, 8, and the beginning of exon 9) while 35% of the mutations have been found in the helicase domain extending over 3 kb at the C-terminus of the protein. Although different types of mutations have been identified, no specific genotype-phenotype correlation has been found, suggesting that gene alteration leads to a loss of function irrespective of mutation type. Our aims were to understand the function of the XNP/ATR-X protein better, with specific attention to the functional consequences of mutations to the zinc finger domain. We used monoclonal antibodies directed against the XNP/ATR-X protein and performed immunocytochemical and western blot analyses, which showed altered or absent XNP/ATR-X expression in cells of affected patients. In addition, we used in vitro experiments to show that the zinc finger domain can mediate double stranded DNA binding and found that the DNA binding capacity of mutant forms in ATR-X patients is severely reduced. These data provide insights into the understanding of the functional significance of XNP/ATR-X mutations.
Cardoso
C
C
INSERM U491, Faculté de Médecine de la Timone, 27 Bd Jean Moulin, 13005 Marseille, France.
Lutz
Y
Y
Mignon
C
C
Compe
E
E
Depetris
D
D
Mattei
M G
MG
Fontes
M
M
Colleaux
L
L
D021581:Active Transport, Cell Nucleus; D000911:Antibodies, Monoclonal / Q000276:immunology; D000918:Antibody Specificity / Q000276:immunology; D015153:Blotting, Western; D002467:Cell Nucleus / Q000378:metabolism*; D002478:Cells, Cultured; D004247:DNA / Q000235:genetics / Q000378:metabolism; D004265:DNA Helicases / Q000737:chemistry / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000737:chemistry / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D000939:Epitopes / Q000276:immunology; D005455:Fluorescent Antibody Technique; D015870:Gene Expression; D006801:Humans; D008607:Intellectual Disability / Q000235:genetics*; D008297:Male; D009154:Mutation / Q000235:genetics*; D009687:Nuclear Proteins / Q000737:chemistry / Q000235:genetics* / Q000276:immunology / Q000378:metabolism*; D011485:Protein Binding; D013577:Syndrome; D013789:Thalassemia / Q000235:genetics*; D000075924:X-linked Nuclear Protein; D016335:Zinc Fingers / Q000235:genetics / Q000502:physiology
D000911:Antibodies, Monoclonal; D004268:DNA-Binding Proteins; D000939:Epitopes; D009687:Nuclear Proteins; D004247:DNA; D004265:DNA Helicases; C092332:ATRX protein, human; D000075924:X-linked Nuclear Protein